Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops new monoclonal antibody treatments for psoriasis (PsO) and other inflammatory and immunology (I&I) conditions. The company's name, derived from the words for "skin" and "restoration," reflects its mission to provide therapies for chronic skin diseases that offer patients significant relief. The company's strategy involves using antibody engineering and format innovations on established mechanisms of action. This approach aims to enhance the effectiveness and dosing schedules of existing standard-of-care medicines while reducing technical and biological risks. Oruka Therapeutics' programs focus on treating and potentially modifying diseases by targeting mechanisms with proven efficacy and safety that are involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Oruka Therapeutics' lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company completed its acquisition of Pre-Merger Oruka on August 29, 2024. Pre-Merger Oruka was a pre-clinical stage biotechnology company incorporated on February 6, 2024, to hold rights to intellectual property developed by Paragon Therapeutics, Inc. On August 29, 2024, ARCA biopharma, Inc. changed its name to Oruka Therapeutics, Inc. and its Nasdaq ticker symbol from "ABIO" to "ORKA".